Mercury Laboratories Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Mercury Laboratories Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $394.7K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Mercury Laboratories Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $394.7K Trade | TransData Nexus

Mercury Laboratories Limited

Indian Pharmaceutical Exporter · Gastrointestinal Specialist · $394.7K Total Trade · DGFT Verified

Mercury Laboratories Limited is an Indian pharmaceutical exporter with a total trade value of $394.7K across 2 products in 2 therapeutic categories. Based on 16 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Lactulose ($321.4K), Roxithromycin ($73.2K), .

Mercury Laboratories Limited — Export Portfolio & Destination Treemap

Mercury Laboratories Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Mercury Laboratories Limited? — Company Overview & Market Position

Mercury Laboratories Limited, established in 1962, is a prominent Indian pharmaceutical company headquartered in Vadodara, Gujarat. The company specializes in the manufacturing, marketing, and export of a diverse range of pharmaceutical formulations, with a strong emphasis on mother and child healthcare. Its product portfolio includes tablets, oral liquids, injections, small volume parenterals, and ophthalmic preparations.

Incorporated as a public limited company on February 12, 1982, under the Corporate Identification Number (CIN) L74239MH1982PLC026341, Mercury Laboratories Limited has demonstrated consistent growth and innovation in the pharmaceutical sector. The company is listed on the Bombay Stock Exchange (BSE) under the ticker symbol 538964. As of March 11, 2026, the stock price was ₹780.00, reflecting a 1.04% increase from the previous close.

Mercury Laboratories Limited operates with an authorized capital of ₹25 million and a paid-up capital of ₹12 million. The company employs approximately 503 individuals, underscoring its significant presence in the pharmaceutical manufacturing industry. For more information, visit their official website at www.mercurylabs.com.

What Does Mercury Laboratories Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Lactulose

Product Portfolio — Top 2 by Export Value

Mercury Laboratories Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Lactulose	Gastrointestinal	$321.4K	11	2.4%	6
2	Roxithromycin	Advanced Antibiotics	$73.2K	5	1.8%	8

Mercury Laboratories Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $394.7K. The top category is Gastrointestinal (81.4% of portfolio), followed by Advanced Antibiotics (18.6%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Mercury Laboratories Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Mercury Laboratories Limited boasts a state-of-the-art manufacturing facility spanning 435,600 square feet (approximately 40,468 square meters) in Vadodara, Gujarat. This expansive facility is equipped with modern technology to produce pharmaceutical products that meet international standards and specifications. The manufacturing units are designed to operate in various dosage forms and accommodate a wide range of batch sizes, ensuring flexibility and efficiency in production.

3Key Leadership

The leadership team at Mercury Laboratories Limited is headed by Chief Executive Officer (CEO) and Managing Director (MD) Rajendra Ramanlal Shah, who has been with the company since its inception. Other key executives include Non-Executive Non-Independent Director Dilip Ramanlal Shah, appointed on February 16, 1982, and Non-Executive Non-Independent Director Paresh Jagdishbhai Mistry, appointed on October 1, 2017. The board also includes Independent Chairperson Sanjay Shantilal Patel, appointed on May 14, 2025, and Non-Executive Independent Director Jayantilal Dhaneshwar Raval, appointed on July 24, 2024.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Mercury Laboratories Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Mercury Laboratories Limited has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company exports its pharmaceutical products to approximately 25 countries, including the United States and the United Kingdom. While specific regulatory filings and approvals in these markets are not detailed in the available sources, the company's export activities suggest compliance with international regulatory standards.

2Emerging Markets

The company has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. Mercury Laboratories Limited exports its products to countries such as Ghana, Nigeria, Mozambique, Zambia, Kenya, Ivory Coast, Mauritania, Burundi, Togo, Guatemala, Costa Rica, Peru, and Ecuador. Additionally, the company has obtained approvals from regulatory bodies in these regions, including the Ghana FDA, DPML Ivory Coast, MoH R D Congo, CDDA Sri Lanka, and MoH Cambodia.

3Geographic Strategy

Mercury Laboratories Limited's geographic strategy demonstrates a balanced approach, with a significant focus on both developed and emerging markets. The company's export activities to approximately 25 countries indicate a diversified market presence, reducing reliance on any single region. This diversification strategy helps mitigate concentration risk and positions the company for sustained growth across various global markets.

Mercury Laboratories Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Mercury Laboratories Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not available in the provided sources. However, the company's export activities to the United States suggest compliance with FDA regulations and standards. For comprehensive information, it is recommended to consult the FDA's official database or contact the company directly.

2WHO & EU GMP

Mercury Laboratories Limited's manufacturing facilities are certified with WHO Good Manufacturing Practice (GMP) Unit-1 and Unit-2 certifications, indicating adherence to international quality standards. Additionally, the company has obtained WHO GMP Unit-2 certification, further demonstrating its commitment to quality manufacturing practices.

3CDSCO & Indian Regulatory

Mercury Laboratories Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company has also obtained approvals from state drug controllers and export No Objection Certificates (NOCs), facilitating its export activities. These regulatory approvals underscore the company's compliance with Indian pharmaceutical manufacturing and export regulations.

Mercury Laboratories Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Mercury Laboratories Limited operates in a competitive pharmaceutical industry, with key competitors in overlapping categories such as gastrointestinal and advanced antibiotics. While specific market share comparisons are not detailed in the available sources, the company's export activities to approximately 25 countries indicate a robust market presence. A head-to-head analysis would require access to detailed market data and competitor performance metrics.

2Key Differentiators

Mercury Laboratories Limited's commitment to mother and child healthcare distinguishes it in the pharmaceutical industry. The company's extensive product portfolio across multiple therapy segments, including gynecology, pediatrics, hemostasis, multi-vitamins, and pain management, reflects its dedication to addressing diverse healthcare needs. Additionally, the company's adherence to international quality standards, as evidenced by its WHO GMP certifications, enhances its competitive advantage.

3Strategic Position

Mercury Laboratories Limited's current strategic direction focuses on the development and marketing of generic pharmaceutical formulations, with a strong emphasis on mother and child healthcare. The company's expansion into emerging markets and adherence to international quality standards position it for sustained growth. Future outlooks may include diversification into specialty pharmaceuticals, biosimilars, or Contract Development and Manufacturing Organization (CDMO) services, contingent upon market dynamics and strategic objectives.

Buyer Due Diligence Brief — Evaluating Mercury Laboratories Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Mercury Laboratories Limited has a track record of consistent export volume and reliability, as evidenced by its export activities to approximately 25 countries. The company's adherence to international quality standards, including WHO GMP certifications, underscores its commitment to delivering high-quality pharmaceutical products. Reliability indicators such as on-time delivery and compliance with regulatory standards further enhance its reputation as a dependable supplier.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Registration: Confirm the company's registration status with the FDA to ensure compliance with U.S. regulations.

WHO GMP Certification: Verify the WHO GMP certifications to ensure adherence to international manufacturing standards.

EU GMP Certification: Check for EU GMP certifications to confirm compliance with European manufacturing standards.

Frequently Asked Questions — Mercury Laboratories Limited

How many pharmaceutical products does Mercury Laboratories Limited export from India?

Mercury Laboratories Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Lactulose ($321.4K), Roxithromycin ($73.2K). Total export value is $394.7K.

What is Mercury Laboratories Limited's total pharmaceutical export value?

Mercury Laboratories Limited's total pharmaceutical export value is $394.7K, based on 16 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Mercury Laboratories Limited cover?

Mercury Laboratories Limited exports across 2 therapeutic categories. The largest are Gastrointestinal (81.4%, 1 products), Advanced Antibiotics (18.6%, 1 products).

Get Full Mercury Laboratories Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.